Gooptu, Bibek and Miranda, E. and Nobeli, Irene and Mallya, M. and Purkiss, Andrew G. and Leigh Brown, S.C. and Summers, C. and Phillips, R.L. and Lomas, D.A. and Barrett, Tracey E. (2009) Crystallographic and cellular characterisation of two mechanisms stabilising the native fold of 1-Antitrypsin: implications for disease and drug design. Journal of Molecular Biology 387 (4), pp. 857-868. ISSN 0022-2836.

Usage Guidelines:
Please refer to usage guidelines at lib-eprints@bbk.ac.uk.
Crystallographic and Cellular Characterisation of Two Mechanisms Stabilising the Native Fold of α1-Antitrypsin: Implications for Disease and Drug Design

Bibek Gooptu1*, Elena Miranda2, Irene Nobeli1, Meera Mallya2, Andrew Purkiss1, Sarah C. Leigh Brown2, Charlotte Summers2, Russell L. Phillips2, David A. Lomas2† and Tracey E. Barrett1†

1School of Crystallography, Birkbeck College, University of London, Malet Street, London WC1E 7HX, UK
2Department of Medicine, University of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Hills Road, Cambridge CB2 0XY, UK

Received 16 January 2009; accepted 31 January 2009
Available online 14 February 2009

Introduction

The plasma protein α1-antitrypsin is principally synthesised by hepatocytes and protects lung tissue from degradation by inhibiting neutrophil elastase.1 It is the archetypal member of the serpin (serine protease inhibitor) superfamily of proteins.2 In common with other inhibitory serpins, the native fold of α1-antitrypsin is metastable and this property is utilised in the characteristic serpin mechanism of action.3 The reactive loop of the molecule is oriented into solution as an ideal substrate for its target protease. Following docking, elastase cleaves the P1–P1′ bond of α1-antitrypsin, allowing the P1–P14 residues of the reactive loop to insert as an additional strand within β-sheet A. The enzyme remains bound to the P1 residue in a catalytic intermediate state and is translocated 70 Å from one pole of the molecule to the other.5 The energy released by the formation of the new β-strand disables the catalytic site and stabilises the

Keywords: serpin; α1-antitrypsin; polymerisation; rational drug design; conformational disease

*Corresponding author. E-mail address: b.gooptu@mail.cryst.bbk.ac.uk.
†D.A.L. and T.E.B. are joint senior authors.
Abbreviations used: serpin, serine protease inhibitor; PDB, Protein Data Bank; NCS noncrystallographic symmetry; TUG, transverse urea gradient; PEG, polyethylene glycol.

2009 Elsevier Ltd. Open access under CC BY license.
covalently bound complex, which is then rapidly cleared from the circulation.6

This dynamic mechanism renders α₁-antitrypsin vulnerable to point mutations, predisposing it to alternative, pathogenic, conformational transitions—in particular self-association into polymer chains.7 These accumulate within the endoplasmic reticulum of hepatocytes rather than enter the circulation. The most clinically significant of these is the Z mutation (Glu342Lys) carried by 1 in 27 of North European...
populations. Homozygotes for the Z allele have deficiency of circulating α1-antitrypsin with levels that are 10–15% of those found in homozygotes for M (wild type) α1-antitrypsin. Disease ensues from both the toxic effects of polymers aggregated within hepatocytes (neonatal hepatitis, cirrhosis and hepatocellular carcinoma) and the loss of antiprotease activity within the lung (emphysema).

Over the last 15 years, biochemical, biophysical and structural studies have defined the general scheme of α1-antitrypsin polymerisation. This proceeds via an initial monomeric intermediate termed M* in a conformation that is activated for the formation of polymers. The existence of this initiating species is indicated by fluorescence studies of α1-antitrypsin polymerisation kinetics and by the structure of the thermodynamically stabilised yet highly polymerogenic α conformer of the closely related protein, α1-antichymotrypsin. These studies support the hypothesis that the native-to-M* transition results from dysregulated opening of β-sheet A and allows the reactive site loop of a neighbouring molecule to insert aberrantly as an extra β-strand. Successive intermolecular loop–sheet interactions lengthen the polymer chain. Recently, an alternative model has been proposed, based upon the structure of a self-terminating dimer of the serpin antithrombin, emphasising polymerisation as an alternative endpoint on the folding pathway.

The repeating subunit of the proposed polymer is considerably unfolded compared to the native structure with intermolecular linkage occurring via a β-hairpin formed from the reactive loop and a contiguous β-strand.

Both proposed mechanisms of polymerisation share key characteristics that can be exploited for the purposes of rational drug design. In both cases, increasing stability of the native fold will reduce the population of the unstable intermediate. Moreover, in both cases, polymerisation requires expansion of β-sheet A and the formation of a six-stranded sheet. For α1-antitrypsin, this involves the sealing of an solvent-accessible cavity flanking β-sheet A. This, therefore, represents an attractive target for rational drug design as small molecules binding here will impede expansion of β-sheet A and, thus, prevent polymerisation by an allosteric mechanism. Evidence for this comes from the effects of mutating either of two residues bordering the cavity—Thr114 and Gly117—to phenylalanine. Both mutations reduce polymerisation of α1-antitrypsin by an order of magnitude in vitro whilst leaving inhibitory activity unaffected. Moreover, both mutations partially rescue the defect in the total levels of secreted Z α1-antitrypsin in a eukaryotic cell model of disease. The importance of this cavity is

![Figure 1](image-url)
highlighted by in silico screens that have identified lead compounds that could fill the cavity and, hence, reduce polymerisation. However, unlike the mutations, all compounds that have proven effective in vitro have also abolished inhibitory activity.

To understand the structural mechanisms by which the effects of the Thr114Phe and Gly117Phe mutations are conferred, we have crystallised both α1-antitrypsin variants and solved their structures to 2.2 and 3.2 Å, resolution, respectively. The structure of Thr114Phe α1-antitrypsin allows us to define a novel target for pharmacophores to block polymer formation whilst preserving inhibitory activity. The structure of the Gly117Phe mutant shows that this mutation exerts its effects by changes in both local packing and the position of the F helix. We have gone on to demonstrate that the two mutations ameliorate the defect in folding of Z α1-antitrypsin to the native, functional conformation in a COS-7 cell secretion model. These features extend our understanding of the balance between fold stability and metastability in α1-antitrypsin. The data are consistent with both proposed β-sheet-A-linked mechanisms of polymerisation. However, in the case of the single-strand linkage model, they can be integrated with previous findings to propose a coordinated mechanism of β-sheet A expansion from the native monomeric protein.

Results and Discussion

Effects of the Thr114Phe mutation arise from partial cavity blockade

The 2.2 Å crystal structure of Thr114Phe α1-antitrypsin adopts the classic structure of a serpin fold in the native conformation (Fig. 1a and Table 1). The polypeptide chain spanning residues 24–393 is highly ordered with the exception of residues 344–351. These comprise the P15–P8 section of the reactive loop, a section that is disordered or associated with high β-factors in other crystal structures of metastable serpins. The key P1 methionine residue that defines the inhibitory specificity of a serpin adopts a canonical conformation.

Comparison of the structure of Thr114Phe α1-antitrypsin with the 2.0-Å structure of wild-type α1-antitrypsin that is also in the native conformation [Protein Data Bank (PDB) code: 1QLP] shows a high degree of overall similarity between the two proteins (Fig. 1b). The root-mean-square deviation (r.m.s.d.) of the mutant and wild-type structures, based on Cα positions, is 0.4 Å. A number of critical regulators of conformational change in α1-antitrypsin have previously been characterised. Apart from the cavity flanking β-sheet A, these are the proximal hinge of the reactive loop,19 the arginine pocket stabilising the loop at the P5 position,20 interstrand spacing in β-sheet A,23 strand 1 of β-sheet C,26 the F helix9,12,27,28 and the shutter region25 (Fig. 1a). These are essentially unchanged in the mutant structure compared to that of wild-type α1-antitrypsin.

| Table 1. X-ray data collection and refinement statistics for structures of Thr114Phe α1-antitrypsin and Gly117Phe α1-antitrypsin |
|------------------|------------------|
|                   | Thr114Phe α1-antitrypsin | Gly117Phe α1-antitrypsin |
| **Data collection** |                     |                     |
| Cell dimensions   |                     |                     |
| a (Å)             | 113.8              | 58.8                |
| b (Å)             | 39.6               | 149.3               |
| c (Å)             | 90.3               | 77.3                |
| β (°)             | 105.1              | 94.11               |
| Molecules in asymmetric unit | 1                | 3                    |
| Space group       | C2                 | P2                  |
| Resolution range (Å) | 87.0–2.2           | 77.1–3.2            |
| Rsym (%)          | 10.6 (49.3)        | 13.8 (58.8)         |
| Completeness (%)  | 94.2 (90.2)        | 99.7 (99.7)         |
| I/σI              | 15.3 (5.5)         | 11.5 (2.5)          |
| Multiplicity      | 6.8 (6.8)          | 4.7 (4.8)           |
| **Structure refinement** |                     |                     |
| No. of atoms (protein) | 2847            | 8562                |
| No. of atoms (water) | 164               | 29.0                |
| Rfree (%)         | 27.2               | 22.4                |
| Rcryst (%)        | 24.2               | 24.2                |
| Bave Main chain   | 31.8               | 68.3                |
| Side chain        | 34.7               | 74.6                |
| Ramachandran plot statistics (%) |                     |                     |
| Favoured regions  | 89.8               | 74.6                |
| Allowed regions   | 9.0                | 21.7                |
| Generously allowed | 1.2               | 2.8                 |
| Disallowed        | 0.0                | 0.9                 |
| r.m.s.d. from identity |                 |                     |
| Bonds (Å)         | 0.007              | 0.010               |
| Angles (°)        | 1.3                | 1.6                 |

Values in parentheses refer to the highest-resolution shell. 

The lack of perturbation elsewhere in the overall structure of Thr114Phe α1-antitrypsin implies that the mutation must be mediating its effect on the fold stability of native α1-antitrypsin (Fig. 1c) from within the cavity flanking β-sheet A. The cavity is well defined in this high-resolution structure, permitting interpretation of the effect of the mutation on cavity filling at the side-chain level. The precise location of the aromatic side chain of Phe114 was strongly indicated by the initial density seen within the cavity adjacent to residue 114 when this was modelled as an alanine (to minimise model bias) prior to any restrained refinement (Fig. 1d). Phe114 makes no interactions with nearby residues, and therefore, its effects are entirely due to partial filling of the cavity and changes in its packing environment during unfolding and polymerisation. The aromatic group of Phe114 closes the upper part of the cavity (Fig. 1d) with its side chain just 3.7 Å from Leu103 and 4.0 Å from Asn104 at the top of helix D, distances that permit favourable van der Waals contacts. These data support the importance of β-sheet A compaction in stabilising the native conformer against initial unfolding.
Proof-of-principle \textit{in silico} fragment screening based upon the Thr114Phe mutation

The volume partially filling the cavity in Thr114Phe $\alpha_1$-antitrypsin (Fig. 1e) is in a region of high-solvent accessibility in the wild-type protein and also yields the therapeutically desirable combination of effective blockade of polymerisation whilst maintaining inhibitory function. Furthermore, it does not alter the native $\alpha_1$-antitrypsin structure beyond the cavity in any way. It is, therefore, attractive to consider it a refined target or an ideal pharmacophore target, depicted in Fig. 1e as the difference between surface representations of wild-type and Thr114Phe $\alpha_1$-antitrypsin around residue 114. The estimated size of this ideal pharmacophore is 59 Å$^3$, equivalent to 22% of the total cavity volume in wild-type $\alpha_1$-antitrypsin.$^{16}$ A similar reduction in the size of lead compounds compared to those identified by screening against the entire cavity would improve the probability of success in rational drug design.$^{18}$ Lipinski’s ‘Rule of 5’$^{17}$ observes that, in drug development, the molecular weight is $<500$ Da, lipophilic index $(\log P)<5$, $\leq 5$ hydrogen-bond donors, $\leq 10$ hydrogen-bond acceptors. A modified version of this, the ‘Rule of 3’, has been proposed to guide drug design via exploration of a greater diversity of chemical space using still smaller ($<300$ Da) molecular fragments to identify potential ‘hits’.$^{19}$ The mean change in $M_r$ in development from lead compound to drug is $+69$ Da, and most effective drugs used in clinical practice are $250–320$ Da.$^{19}$ Currently, the lead compounds designed to block the entire cavity and shown to be effective \textit{in vitro} are at the upper end of the desirable drug size ($310–650$ Da).$^{12}$

To consider the region occupied by the Thr114Phe mutation a meaningful pharmacophore target, it must generate hits \textit{in silico} that are plausible in terms of mimicking the mutation’s partial cavity blockade, their predicted binding plausible in terms of mimicking the mutation’s direction and binding, respectively. On the other hand, unlike the entire cavity, this region is only bounded by residues in one plane, which may be challenging for some docking strategies. These considerations make it hard to assume \textit{a priori} that plausible docking candidates would emerge \textit{in silico} screening of fragment libraries.

We have therefore performed a proof-of-concept screen of $>70,000$ fragments with $M_r=150–250$ Da to assess the potential of the new pharmacophore for identifying small compounds that can be developed in rational drug design. The pharmacophore centroid was set as the midpoint between Thr114 (mutation site, middle of $\beta$2A) and Asn104 (top of helix D) for the purposes of our protocol. Screens were performed to select hits on the basis of docking scores and ligand–target centroid proximity. By definition, all hits obey the Rule of 5 and can only deviate from the Rule of 3 a single hydrogen-bond acceptor. The best-scoring 0.1% of ligands were taken forward for induced fit docking, resulting in optimised docking of 65 unique ligands. These had the following mean (±SD) characteristics: $M_r=207.2$ Da (±21.7), estimated $(\log P)$ value=1.76 (±0.81) and ligand–pharmacophore centroid proximity=5.16 Å (±0.76). The fragments are shown docked ensemble in relation to residues 104, 114 and 139 (Fig. 1f, left). The best docking scores and proximity to the pharmacophore centroid and sizes of all ligands docked by the induced fitting protocol are also shown (Fig. 1f, right).

Docking scores calculated by Glide SP correlate with predicted $K_d$ values such that a value $<6.8$ kcal/mol correlates with a predicted micromolar $K_d$ and a value $<8.2$ kcal/mol correlates with submicromolar affinity. Figure 1f illustrates that this screen identified numerous fragment hits achieving scores within this range. Examples of docked ligands ranked highly by docking scores and fragment–target centroid proximity are shown in Fig. 1g.

Optimisation of this strategy is likely to require screening 1–2 orders of magnitude more fragments and ‘growing’ (up to $M_r=250$ Da) of the best hits to optimise specificity and drug-likeness ahead of \textit{in vitro} testing. However, the hits identified by this preliminary screen are good candidates in terms of size, predicted binding affinities and drug-likeness for further development. Moreover, our screen also identified compounds that docked well to sites above the pharmacophore target site or interacted with the front of $\beta$-sheet A (Fig. 1f). Similar hits will aid the ‘growing’ of compounds for future \textit{in vitro} testing.

The Gly117Phe mutation alters aromatic ring packing in the interface of $\beta$-sheet A with the $F$-helix interface and induces a half-turn downward shift in $F$-helix position

The structure of Gly117Phe $\alpha_1$-antitrypsin was solved to 3.2 Å resolution (Table 1 and Fig. 2a), allowing confident interpretation of the secondary structure of the protein. The asymmetric unit contained three molecules with minimal intermolecular contacts and in an arrangement not suggestive of biologically significant multimerisation. No significant changes are evident in $\beta$-sheet A, the shutter region or strand 1 of $\beta$-sheet C in Gly117Phe $\alpha_1$-antitrypsin relative to the wild-type protein. Electron density was not seen for residues 349–356 (copy A), 348–356 (copy B) and 348–358 (copy C) of the hypermobile reactive site loop.

Before incorporation of the Phe mutation into the model or any restrained refinement had been performed, clear density was apparent at the mutation site, indicating that its side chain was oriented away from $\beta$-sheet A towards the $F$ helix where significant changes were seen. To investigate

Crystal Structures of Thr114Phe and Gly117Phe $\alpha_1$-Antitrypsin
these changes, we omitted the mutation site and the overlying part of the F helix to generate a difference density map of these areas with model bias minimised. This was based upon the initial rigid-body fit of the search model and did not use noncrystallographic symmetry (NCS) restraints, yet it confirmed a half-turn shift of the F-helix along its axis for all three molecules as well as side-chain density for the underlying Phe117 residue (Fig. 2a, boxed). In the refined structure, the F-helix is displaced downwards (towards the bottom of s3A) by half a turn relative to its position in the structure.
of native wild-type α₁-antitrypsin (2.7–3.5 Å between equivalent Ca atoms). This compares with an overall Cα r.m.s.d. of 1.2 Å for the rest of the two structures. The F-helix shift is unlikely to be an artefact of crystal packing as different copies of Gly117Phe α₁-antitrypsin have different packing environments. Moreover, no F-helix changes are required to permit packing of three molecules of the native wild-type protein in orientations identical with those of the three copies of Gly117Phe α₁-antitrypsin in the asymmetric unit (not shown). Conversely, repacking of helix F–β-sheet A interface residues, in particular Tyr160, is necessary to avoid steric clashes with the adjacent Phe117 side chain and sustain favourable hydrophobic interactions. Figure 2b compares packing of the helix F–β-sheet A interface in wild-type and Gly117Phe α₁-antitrypsin. In the refined structure of Gly117Phe α₁-antitrypsin, Phe117 forms the centre of a cluster of aromatic side chains, interacting with Phe119, Phe143 and Tyr187 (all at distances of 3.5–5.5 Å). The side chain of Tyr160 is in a solvent-exposed position in this mutant in contrast to its buried position within the helix F–β-sheet A interface in wild-type α₁-antitrypsin but remains well placed for aromatic interactions with two residues of this cluster, Phe119 and Phe143. These differences therefore account for the changed conformation of helix F in Gly117Phe α₁-antitrypsin compared to the wild-type protein. They introduce an extra aromatic ring into the helix F–β-sheet A interface in the mutant to increase favourable packing interactions between strands 1–3 of the β-sheet. These changes do not obviously increase the degree of hydrophobic interaction between the F helix (or its linker to s3A, both shown in gold) and β-sheet A (blue). However, it is striking that the biochemistry of this mutant resembles that of α₁-antitrypsin, carrying what can now be regarded as a complementary mutation, Tyr160Trp. Here, an extra aromatic ring is introduced from the F-helix side into the helix F–β-sheet A interface to project into a site adjacent to Gly117. The Tyr160Trp mutation is associated with a near-identical increase in thermal stability to that seen with the Gly117Phe mutation. Both mutations are also alike in achieving this without any reduction in inhibitory activity. The increased biochemical stability conferred by the Gly117Phe mutation on the native fold of α₁-antitrypsin (Fig. 2c) is therefore related to increased stabilisation of the F helix. The relative contributions of the alterations in packing of the helix F–β-sheet A interface and its half-turn displacement towards the lower pole of the molecule remain to be determined. Since these effects involve alterations of the final folding of native α₁-antitrypsin and are mediated via interactions in a hydrophobic interface, they may be hard to mimic via rational drug design. However, the fact that the position of the F helix is affected in the absence of any other significant changes to the overall fold supports the conclusion that this helix forms relatively late in the folding process and independent from the folding of other structural features.

Effect of Thr114Phe and Gly117Phe mutations on secretion of Z α₁-antitrypsin from COS-7 cells

To relate our findings to drug design for α₁-antitrypsin deficiency, we attempted to characterise the stability and folding of the Thr114Phe/Z and Gly117Phe/Z double mutants of α₁-antitrypsin. These were produced as recombinant proteins using the same overexpression system as the crystallised proteins and purified by the same method. The yield of both double mutants was between 1 and 2 orders of magnitude lower than that of wild-type and single-Phe mutant α₁-antitrypsin. The products were conformationally heterogeneous with a mixture of native, latent [the major product on non-denaturing and urea polyacrylamide gel electrophoresis (PAGE) and polymeric conformers. The effects of the Thr114Phe and Gly117Phe mutations on transient expression and secretion of α₁-antitrypsin containing the Z mutation in a more physiological, eukaryotic cell system were then assessed. Previous work has shown that the Thr114Phe and Gly117Phe mutations partially rescue the profound defect in the overall secretion of α₁-antitrypsin caused by the Z mutation in a Xenopus oocyte system.14 These effects are modest in proportion to the overall deficit but are of considerable clinical interest since disease severity correlates closely with rates of polymerisation and (inversely) with circulating levels of α₁-antitrypsin.30 However, this study did not characterise the conformational state of the secreted material. We therefore transformed and transiently expressed M, Z, Thr114Phe/Z and Gly117Phe/Z α₁-antitrypsin in COS-7 cells. Analysis of cell lysates and culture media by Western blot analysis of sodium dodecyl sulfate (SDS)-PAGE showed increased secretion of α₁-antitrypsin in the double mutants compared with Z α₁-antitrypsin (Fig. 3a and b). These data were consistent with those quantified by the more sensitive pulse-chase system in Xenopus oocytes. This increase in total α₁-antitrypsin secretion was related to a clear increase in secretion of native, monomeric α₁-antitrypsin as assessed by Western blot analysis of non-denaturing PAGE (Fig. 3c, arrow). The absolute concentrations of α₁-antitrypsin in the culture media were very low relative to those conventionally used to measure the inhibitory activity of α₁-antitrypsin. However, we were able to detect inhibitory activity using an ELISA technique in which bovine α-chymotrypsin was used to capture functional α₁-antitrypsin from concentrated culture media. This indicated that more functional material was secreted in the presence of the double mutations (1.35 μg/ml for Thr114Phe/Z and 0.35 μg/ml for Gly117Phe/Z α₁-antitrypsin) than with the Z mutation alone (<0.16 μg/ml of active protein; below linear range of detection by ELISA). These effects were modest compared with the amount of functional M α₁-antitrypsin detected in the culture media (>5 μg/ml; exceeding the maximum assessable in
the linear range of the ELISA) but were consistent with the appearance of native protein by non-denaturing PAGE (Fig. 3c).

The increased secretion of native α1-antitrypsin from cells expressing the double mutants compared to those expressing Z α1-antitrypsin was also associated with an increase in the amount of polymeric material seen in the media. We cannot formally exclude the possibility that these polymers were formed intracellularly and then secreted differentially. However, the lack of any observable difference in total and polymeric intracellular α1-antitrypsin levels between the different constructs does not support this hypothesis. We therefore favour the alternative explanation that the extracellular polymers are formed from α1-antitrypsin that is secreted in the native conformation. Taken together, these data support the conclusion that the Thr114Phe and Gly117Phe mutations have modest but detectable effects on increasing secretion of functional native α1-antitrypsin on the background of the severe Z mutation in eukaryotic cells. However, these double mutants remain prone to conformational change and polymerisation.

Relating the crystal structures of Thr114Phe and Gly117Phe α1-antitrypsin to the single- and double-strand linkage models of polymerisation

The Thr114Phe and Gly117Phe mutations act by different mechanisms to increase the global stability of native α1-antitrypsin. Expansion of β-sheet A is a common feature in both proposed mechanisms of polymerisation.9,13 In order for α1-antitrypsin to adopt either M* conformation, residue 114 must move laterally by 4.6 Å in the plane of β-sheet A. This is limited by local steric clashes in Thr114Phe α1-antitrypsin. In the case of the Gly117Phe mutation, the structural mechanism whereby the changes in the vicinity of the F helix may impede formation of a β-hairpin donor/acceptor M* species is less intuitive. There is no apparent increase in stabilising interactions between the helix F–s3A linkers and s5A, and the changes in packing in the interface between the F helix and β-sheet A would not of themselves be expected to impede opening of the β-sheet. Nevertheless, our data are not inconsistent with this model since they may simply reflect overall cooperativity of the final steps on the folding pathway (and initial steps on the unfolding pathway) for α1-antitrypsin. However, our findings can be mechanistically integrated with other biochemical data for the native-to-M* transition posited for the single-strand linkage model in which opening of the s4A site is associated with partial intramolecular loop insertion. Various data support the following features of this model: upper s4A opening precedes lower s4A opening9,25,31,32 and is associated with partial insertion of the reactive site loop.9,33,34 Subsequent lower s4A opening around the site of P8 residue insertion is associated with breaking of a network of interactions between s4A, s5A and shutter region residues.35 This can be induced by the insertion of a cleaved reactive loop or a peptide analogue into β-sheet A from the P14–P9 sites, producing species that are highly polymerogenic.31,32,35,36 In α1-antitrypsin, modelling the insertion of the reactive site loop to the P12 position necessitates both the release of s1C and remodelling of the upper helix F—secondary structural changes known to occur during the formation of polymers from native α1-antitrypsin.12,26 However, stabilisation of the upper turns of the F helix and/or its downward displacement as seen in the structure of Gly117Phe α1-antitrypsin will reduce the propensity for its remodelling. It will, therefore, reduce M* formation if such remodelling is integral to the formation of the intermediate. This process is shown as a schema in Fig. 4. The model of the single-strand donor/acceptor M* is shown following energy minimisation and simulated annealing molecular dynamics (coordinates are supplied as Supplementary Data).

Conclusion

The data presented here demonstrate in crystallographic detail two mechanisms that greatly stabilise the native fold in α1-antitrypsin without abolishing its inhibitory function. These mechanisms are likely to
underlie the partial rescue of secretion of native α1-antitrypsin when the Thr114Phe or Gly117Phe mutations occur in the context of the Z mutation in eukaryotic cells although the double mutants remain highly polymerogenic. The high-resolution structural characterisation of the Thr114Phe mutation presents a more precise pharmacophore target for screening of small fragments capable of mimicking its effects. These data are generally consistent with either the single-strand or β-hairpin linkage models of polymerisation. However, they suggest a specific mechanism of propagated conformational change in the case of the single-strand model and, therefore, open up new approaches for further studies to test its applicability in this important pathological pathway.

**Materials and Methods**

**Site-directed mutagenesis, protein expression, purification and characterisation**

QuikChange mutagenesis (Stratagene, California, USA) was used to introduce the Thr114Phe, Gly117Phe and/or Z (Glu342Lys) mutations into His-tagged α1-antitrypsin in the pQE31 vector37 to create single- or double-mutant constructs. The full-length sequences of the mutated α1-antitrypsin genes were confirmed, and plasmids were transformed into XL-1 Blue *Escherichia coli* cells. The wild-type and mutant proteins were expressed and purified as described previously.14 The final products were stored in 10 mM Tris/HCl, pH 7.4, 10 mM NaCl and 1 mM ethylenediaminetetraacetic acid. Product purities were confirmed by non-denaturing PAGE, SDS-PAGE and transverse urea gradient (TUG)-PAGE. Further characterisation of urea stability by circular dichroism (CD) was performed as described previously.

Fig. 4. Schema for formation of a partially loop-inserted M* species from native α1-antitrypsin. Findings from the Thr114Phe and Gly117Phe α1-antitrypsin crystal structures are incorporated together with previous observations of requirements for loss of the s1C strand, remodeling of the F helix9,12,28 and destabilising of interactions involving shutter region residues.25 Sequential insertion of the reactive loop into the upper s4A position is depicted by two chimeras. These are derived from structures of native (1QLP) and latent (1IZ2) α1-antitrypsin, murine α1-antichymotrypsin (1YXA—demonstrating changes associated with opening of the P14 acceptor site) and thyroxine binding globulin (2CEO—demonstrating changes on expansion at the P12 insertion site). In all cases, the reactive loop modelled is that of α1-antitrypsin. The final image shows the α1-antitrypsin M* model, generated as described in Materials and Methods, after opening the lower s4A position directly (e.g., Siliyama).
bovine α-chymotrypsin. The plate was then washed before incubating for 15 min at 37 °C with 100 μl of culture medium concentrated 7.5 times (this did not affect relative proportions of polymeric to total α1-antitrypsin). After further washing to remove unbound material, the amount of functional material captured was assessed by incubation with 100 μl of purified polyclonal antibody against α1-antitrypsin used at 1 μg/ml for 2 h at 4 °C in the presence of 0.25% (w/v) bovine serum albumin as a blocking agent, followed by washing and incubation with 100 μl of hors eradish-peroxidase-conjugated anti-rabbit secondary antibody (Sigma-Aldrich, Dorset, UK). The plate was washed and the enzymatic activity was calculated by subtracting the volume of the cavity in the mutant from that in the wild-type protein. Similarly, an ideal pharmacophore capable of mimicking the partial cavity blockade caused by the mutation was illustrated by subtraction of the surface map of residue 114 in wild-type α1-antitrypsin from that of Thr114Phe α1-antitrypsin using SURFNET.48

**In silico screens of compound libraries**

The fragment-like subset of the ZINC database∂ (−2 ≤xLogP ≤3, Mᵢ = 150–250 Da, ≤3 rotational bonds, ≤2 hydrogen-bond donors and ≤4 hydrogen-bond acceptors) was selected for initial prescreening to identify drug- and lead-like compounds capable of significant modification to optimise specificity without unfavourably increasing size. The subset labelled 'usual', containing all fragment-like molecules protonated in the pH range 5.75 to 8.25, was downloaded. Programs from the Schrödinger Suite 2007 (Schrödinger LLP, New York, NY, USA) were used for in silico docking. Fragments were preprocessed using LigPrep version 2.1. The original ionisation state was retained and 'desalt' and 'tautomeration' flag settings were used. Chiralities were determined from the original ZINC database structures, and one low-energy ring conformation was allowed. This procedure resulted in a total of 70,925 small-molecule structures for docking. The protein was prepared using Maestro version 8.0 (Protein Preparation Wizard). Hyd rog ens were added, and all waters were deleted from the structure of wild-type α1-antitrypsin. Hydrogen bonds were optimised, and the structure was minimised within 0.30 Å r.m.s.d. from the initial structure. The potential energy grid was pre-calculated using a box centred on the centroid of residues Asn104 and Thr114 to prepare the binding site for docking. The box was 39 Å in each dimension, but the ligand centre was constrained to lie within 14 Å of the box centre. No additional constraints were used.

Initial screening of the 70,925 ligands was performed using Glide version 4.5, to generate a range of putative ligand-receptor interactions (poses). The best pose for each ligand was calculated using Emodel and retained. Ranking between ligands was then performed using the Glide SP score. All Glide parameters were left to their default values. The top 70 (<0.1%) ligands resulting from this Glide SP run were then submitted to the Induced Fit Docking protocol, a three-step docking process. Preliminary docking by Glide SP used a scaling factor for van der Waals radii of 0.5 for both the ligand and the receptor. For each ligand, the best 20 poses were retained. Prime version 1.6 was used to optimise receptor side chains within 5.0 Å of each posed ligand. Finally, ligands were redocked into the optimised structures. The resulting poses were ranked using a composite of the Glide SP (binding site energy) and the Prime (molecular mechanics + solvation energy function for the protein–ligand complex) scores as previously described.49

The molecular weight and other descriptors for the set of docked ligands were calculated using the MOE suite (MOE 2006.08, Chemical Computing Group, Montreal, QC, Canada). Prior to descriptor calculation, the partial charges on all atoms were recalculated using the default MOE force field (MMFF94x), and adjustment of hydrogens and lone pairs was allowed.

**Modelling α1-antitrypsin in the M* conformation**

To model wild-type and mutant α1-antitrypsin in the partially loop-inserted M* conformation, we used the 2.2-
A crystal structure of latent α1-antitrypsin (IQLP) as the initial template. In the latent conformation, the reactive loop is fully inserted into β-sheet A as its fourth strand (s4A). This structure was chosen as it is the highest-resolution structure of α1-antitrypsin with an expanded β-sheet A. Mutations were restored back to the wild-type sequence. The residues of the reactive site loop were threaded into the conformation adopted in the structure of δ Leu55Pro α1-antichymotrypsin (1QMN) using SWISS-MODEL. As the reactive loop of α1-antitrypsin is four residues shorter than that of α1-antichymotrypsin, this required stripping out of sIC to connect it directly with s4B. The model was regularised in Coot before undergoing energy minimisation, simulated annealing and final energy minimisation using SANDER, with the protein parameterised using the AMBER99SB force field. The upper turn of helix F required greater freedom during simulated annealing than the rest of the molecule to allow successful energy minimisation. This was achieved by conservative relaxation of restraints on this region relative to the rest of the molecule.

Accession numbers

Coordinates and structure factors are deposited in the PDB with accession number 3DRM for the structure of Thr114Phe α1-antitrypsin and 3DRU for the structure of Gly117Phe α1-antitrypsin.

Acknowledgements

This work was supported by a Wellcome Trust Intermediate Clinical Fellowship to B.G., an Alpha1-antitrypsin Laurell Training Award award to M.M., a Wellcome Trust summer studentship to S.C.L.B., a Wellcome Trust Clinical Training Fellowship to R.L. P., the Medical Research Council (UK), the British Pharmaceutical Society and Papworth National Health Service Trust. C.S. is a Wellcome Trust Research Training Fellow. We thank Dr Nora Cronin (School of Crystallography, Birkbeck College, University of London) for her assistance in collecting crystallographic data and Ms Heike Kröger (Cambridge Institute for Medical Research) for her assistance with the cell biological experiments.

Supplementary Data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.jmb.2009.01.069

References

1. Baugh, R. J. & Travis, J. (1976). Human leukocyte granule elastase: rapid isolation and characterization. Biochemistry, 15, 836–841.
2. Silverman, G. A., Bird, P. I., Carrell, R. W., Church, F. C., Coughlin, P. B., Gettins, P. et al. (2001). The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, novel functions, mechanism of inhibition and a revised nomenclature. J. Biol. Chem. 276, 33293–33296.
3. Huber, R. & Carrell, R. W. (1989). Implications of the three-dimensional structure of α1-antitrypsin for structure and function of serpins. Biochemistry, 28, 8951–8966.
4. Schechter, I. & Berger, A. (1967). On the size of the active site in proteases. 1. Papain. Biochem. Biophys. Res. Commun. 27, 157–162.
5. Huntington, J. A., Read, R. J. & Carrell, R. W. (2000). Structure of a serpin–protease complex shows inhibition by deformation. Nature, 407, 925–926.
6. Mast, A. E., Englund, J. J., Pizzo, S. V. & Salvesen, G. (1991). Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of α1-proteinase inhibitor, α1-antichymotrypsin, antithrombin III, α2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry, 30, 1723–1730.
7. Lomas, D. A., Evans, D. L., Finch, J. T. & Carrell, R. W. (1992). The mechanism of Z α1-antitrypsin accumulation in the liver. Nature, 357, 605–607.
8. Dafforn, T. R., Mahadeva, R., Elliott, P. R., Sivasothy, P. & Lomas, D. A. (1999). A kinetic mechanism for the polymerisation of α1-antitrypsin. J. Biol. Chem. 274, 9548–9555.
9. Goopetu, B., Hazes, B., Chang, W.-S. W., Dafforn, T. R., Carrell, R. W., Read, R. & Lomas, D. A. (2000). Inactive conformation of the serpin α1-antichymotrypsin indicates two stage insertion of the reactive loop; implications for inhibitory function and conformational disease. Proc. Natl Acad. Sci. USA, 97, 67–72.
10. Sivasothy, P., Dafforn, T. R., Gettins, P. G. W. & Lomas, D. A. (2000). Pathogenic α1-antitrypsin polymers are formed by reactive loop–β-sheet A linkage. J. Biol. Chem. 275, 33663–33668.
11. James, E. L. & Bottomley, S. P. (1998). The mechanism of α1-antitrypsin polymerization probed by fluorescence spectroscopy. Arch. Biochem. Biophys. 356, 296–300.
12. Cabrita, L. D., Dai, W. & Bottomley, S. P. (2004). Different conformational changes within the F-helix occur during serpin folding, polymerization and proteinase inhibition. Biochemistry, 43, 9834–9839.
13. Yamasaki, M., Li, W., Johnson, D. J. & Huntington, J. A. (2008). Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature, 455, 1255–1258.
14. Parfrey, H., Mahadeva, R., Ravenhill, N., Zhou, A., Dafforn, T. R., Foreman, R. C. & Lomas, D. A. (2003). Targeting a surface cavity of α1-antitrypsin to prevent conformational disease. J. Biol. Chem. 278, 33060–33066.
15. Mallya, M., Phillips, R. L., Saldanha, S. A., Goopetu, B., Leigh Brown, S. C., Termine, D. J. et al. (2007). Small molecules block the polymerization of Z alpha1-antitrypsin and increase the clearance of intracellular aggregates. J. Med. Chem. 50, 5357–5363.
16. Elliott, P. R., Pei, X. Y., Dafforn, T. R. & Lomas, D. A. (2000). Topography of a 2.0 Å structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci. 9, 1274–1291.
17. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 23, 3–25.
18. Carr, R. A. E., Congreve, M., Murray, C. W. & Rees, D. C. (2005). Fragment-based lead discovery: leads by design. Drug Discovery Today, 10, 987–992.
19. Leach, A. R., Hann, M. M., Burrows, J. N. & Griffen, E. J. (2006). Fragment screening: an introduction. Mol. Biosyst. 2, 429–446.

20. Baglin, T. P., Carrell, R. W., Church, F. C., Esmon, C. T. & Huntington, J. A. (2002). Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc. Natl Acad. Sci. USA, 99, 11079–11084.

21. McGowan, S., Buckle, A. M., Irving, J. A., Ong, P. C., Bashantnyk-Puhalovich, T. A., Kan, W. T. et al. (2006). X-ray crystal structure of MENT: evidence for functional loop–sheet polymers in chromatin condensation. EMBO J. 25, 314–3155.

22. Jin, L., Abrahams, J.-P., Skinner, R., Petitou, M., Pike, R. & Carrell, R. W. (1997). The anticoagulant activation of antithrombin by heparin. Proc. Natl Acad. Sci. USA, 94, 14683–14688.

23. Aulak, K. S., Eldering, E., Hack, C. E., Lubbers, Y. P. T., Harrison, R. A., Mast, A. et al. (1993). A hinge region mutation in CI-inhibitor (Ala386 -> Thr) results in nonsubstrate-like behavior in and polymerization of the molecule. J. Biol. Chem. 268, 18088–18094.

24. Elliott, P. R., Abrahams, J.-P. & Lomas, D. A. (1998). Wildtype α1-antitrypsin is in the canonical inhibitory conformation. J. Mol. Biol. 275, 419–425.

25. Zhou, A., Stein, P. E., Huntington, J. A. & Carrell, R. W. (2003). Serpin polymerisation is prevented by a hydrogen bond network that is centered on His-334 and stabilized by glycerol. J. Biol. Chem. 278, 15116–15122.

26. Chang, W.-S. W., Whistock, J., Hopkins, P. C. R., Lesk, A. M., Carrell, R. W. & Wardell, M. R. (1997). Importance of the release of strand 1C to the serpin inhibitory mechanism is critically dependent on the length of the reactive center loop. J. Biol. Chem. 272, 27541–27547.

27. Tsutsui, Y., Lu, L., Gershenson, A. & Wintrobe, P. L. (2006). The conformational dynamics of a metastable serpin studied by hydrogen exchange and mass spectrometry. Biochemistry, 45, 6561–6569.

28. Cabrita, L. D., Whistock, J. C. & Bottomley, S. P. (2002). Probing the role of the F-helix in serpin stability through a single tryptophan substitution. Biochemistry, 41, 4575–4581.

29. Stein, P. E. & Carrell, R. W. (1995). What do dysfunctional serpins tell us about molecular mobility and disease? Nat. Struct. Biol. 2, 96–113.

30. Mahadeva, R., Chang, W.-S. W., Dafforn, T., Oakley, D. J., Foreman, R. C., Calvin, J. et al. (1999). Heteropolymerisation of S and Z α1-antitrypsin and liver cirrhosis. J. Clin. Invest. 103, 999–1006.

31. Fitton, H. L., Pike, R. N., Carrell, R. W. & Chang, W.-S. W. (1997). Mechanisms of antithrombin polymerisation and heparin activation probed by insertion of synthetic reactive loop peptides. Biol. Chem. 378, 1059–1063.

32. Huntington, J. A., Pannu, N. S., Hazes, B., Read, R., Lomas, D. A. & Carrell, R. W. (1999). A 2.6 Å structure of a serpin polymer and implications for conformational disease. J. Mol. Biol. 293, 449–455.

33. Mahadeva, R., Dafforn, T. R., Carrell, R. W. & Lomas, D. A. (2002). Six-mers peptide selectively anneals to a pathogenic serpin conformation and blocks polymerisation: implications for the prevention of Z α1-antitrypsin related cirrhosis. J. Biol. Chem. 277, 6771–6774.

34. Eldering, E., Verpy, E., Roem, D., Meo, T. & Tosi, M. (1995). COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization. J. Biol. Chem. 270, 2579–2587.

35. Zhou, A., Stein, P. E., Huntington, J. A., Sivasothy, P., Lomas, D. A. & Carrell, R. W. (2004). How small peptides block and reverse serpin polymerization. J. Mol. Biol. 342, 931–941.

36. Dunstone, M. A., Dai, W., Whisstock, J. C., Rossjohn, J., Pike, R. N., Feil, S. C. et al. (2000). Cleaved antitrypsin polymers at atomic resolution. Protein Sci. 9, 417–420.

37. Zhou, A., Carrell, R. W. & Huntington, J. A. (2001). The serpin inhibitory mechanism is critically dependent on the length of the reactive center loop. J. Biol. Chem. 276, 27541–27547.

38. Miranda, E., Romisch, K. & Lomas, D. A. (2004). Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J. Biol. Chem. 279, 28283–28291.

39. Miranda, E., MacLeod, L., Davies, M. J., Perez, J., Romisch, K., Crowther, D. C. & Lomas, D. A. (2008). The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB. Hum. Mol. Genet. 17, 1527–1539.

40. Leslie, A. G. W. (1992). Recent changes to the MOSFLM package for processing film and image data. Joint CCP4 and ESF-EACMB Newsletter on Protein Crystallography, vol. 26. SERC, Daresbury Laboratory, Warrington, UK.

41. Kabach, W. (1988). Evaluation of single crystal X-ray diffraction data from a position sensitive detector. J. Appl. Crystallogr. 21, 916–924.

42. Vagin, A. & Teplyakov, A. (1997). MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30, 1022–1025.

43. Mursudov, G. N., Vagin, A. A. & Dodson, E. J. (1997). Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 53, 240–255.

44. Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, W. et al. (1998). Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 54, 905–921.

45. Emsley, P. & Cowtan, K. (2004). Coot: model-building visualization system for exploratory research and analysis. J. Appl. Crystallogr. 30, 98–103.

46. DeLano, W. L. (2002). The PyMOL Molecular Graphics System. http://www.pymol.org.

47. Petersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C. & Ferrin, T. E. (2004). UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612.

48. Laskowski, R. A. (1995). SURFNET: a program for visualizing molecular surfaces, cavities and intermolecular interactions. J. Mol. Graphics, 13, 323–330.

49. Irwin, J. J. & Shoichet, B. K. (2005). ZINC—a free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45, 177–182.

50. Sherman, W., Day, T., Jacobson, M. P., Freisner, R. A. & Farid, R. (2006). Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 49, 534–553.

51. Im, H., Woo, M.-S., Hwang, K. Y. & Yu, M.-H. (2002). Interactions causing the kinetic trap in serpin protein folding. J. Biol. Chem. 277, 46347–46354.

52. Guex, N. & Peitsch, M. C. (1997). SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis, 18, 2714–2723.

53. Case, D. A., Darden, T. A., Cheatham, T. E., III, Simmerling, C. L., Wang, J., Duke, R. E. et al. (2006). AMBER 9 University of California, San Francisco, CA.